ストックスクリーナーアプリを入手
13.72
8.04%
-1.20
前日終値:
$14.92
開ける：
$14.68
24時間の取引高:
33,785
Relative Volume:
0.49
時価総額：
$123.04M
収益：
-
当期純損益:
$-40.62M
株価収益率:
-0.7069
EPS:
-19.4076
ネットキャッシュフロー:
$-35.63M
1週間 パフォーマンス:
+12.46%
1か月 パフォーマンス:
+4.26%
6か月 パフォーマンス:
-3.11%
1年 パフォーマンス:
-28.83%
1日の値動き範囲:
$13.47
$14.93
1週間の範囲:
$11.25
$17.25
52週間の値動き範囲:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
名前
Promis Neurosciences Inc
セクター
電話
416-847-6898
住所
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
13.72 | 105.10M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Promis Neurosciences Inc (PMN) 最新ニュース
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada
ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus
ProMIS Neurosciences Inc. Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in PRECISE-AD Phase 1b Alzheimer?s Disease Trial - marketscreener.com
ProMIS Neurosciences stock jumps on trial safety data - Investing.com
ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data - TipRanks
ProMIS Neurosciences reports no ARIA‑E and favorable 6‑month biomarker trends for PMN310; 12‑month topline due Q1 2027 - TradingView
ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data - Stock Titan
ProMIS Neurosciences Reports Positive Blinded Six-Month - GlobeNewswire
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Income Statement - TradingKey
ProMIS Neurosciences to present interim Alzheimer’s trial data on PMN310 - TipRanks
ProMIS to host webinar on Alzheimer’s trial interim data - Investing.com
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease - marketscreener.com
Two Alzheimer’s researchers join ProMIS webinar on blinded trial data - Stock Titan
PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
PMN|ProMIS Neurosciences Inc|Price:11.780|Chg%:-0.420 - TradingKey
ProMIS Neurosciences Inc (PMN) Balance Sheet - TradingKey
Chardan initiates ProMIS Neurosciences stock with buy rating By Investing.com - Investing.com Canada
PMN|ProMIS Neurosciences Inc|Price:12.200|Chg%:-0.410 - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Cash Flow - TradingKey
ProMIS Neurosciences Inc. Revenue Breakdown – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN) - The Globe and Mail
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ProMIS reports PMN310 oligomer reduction at 29 days - grafa.com
ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in A - GuruFocus
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 - NTB Kommunikasjon
One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid - Stock Titan
ProMIS Neurosciences Reports Dose-Dependent Reduction of Amyloid-Beta Oligomers for PMN310 in Healthy Volunteers - Quiver Quantitative
ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN - TradingView
PMN Initiated Coverage by Roth Capital -- Rating Set to Buy - GuruFocus
ProMIS Neurosciences (PMN) Slips Marginally, Holds Near Key SupportTick Index - dars.gov.et
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Promis Neurosciences Inc (PMN) 財務データ
収益
当期純利益
現金流量
EPS
Promis Neurosciences Inc (PMN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):